Market Analysis
NVO vs LLY: Which Pharma Stock is Likely to Do Better in 2025?
Obesity market continues to boom, with Novo Nordisk opening the gates wide open with Wegovy.
Total Stories
25
News
pharma stocks
Section
pharma stocks
Market Analysis
Novo Nordisk’s Shares Dip Amid Surprise CEO Exit in Challenging Times for the Firm
Novo Nordisk's surprise CEO departure amid mounting competitive pressures and disappointing clinical results has accelerated the stock's 50% decline since mid-2024.
Market Analysis
Eli Lilly’s Stock Tumbles as Firm Cuts EPS Guidance Despite Strong Q1
Eli Lilly's stock dropped over 7% after announcing a lowered profit forecast, despite exceeding Q1 expectations.
Market Analysis
J&J Stock Dips After $10 Billion Settlement Dismissed by Judge
Johnson & Johnson faces a significant legal setback with the dismissal of its $10 billion settlement proposal related to talc product lawsuits.
Market Analysis
Trump Admin. Reconsiders $590M Funding for Moderna’s Bird Flu Vaccine
The Trump administration is reconsidering a $590 million contract with Moderna for bird flu vaccine development.
Market Analysis
Vertex Pharmaceuticals Stock Soars as Non-Opioid Pain Treatment Gets FDA Nod
Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing acute pain.
Market Analysis
Moderna Cuts 2025 Sales Forecast Amid Low Vaccine Demand, Stock Plummets
Moderna has lowered its 2025 sales forecast due to decreased demand for its Covid and RSV vaccines.
Market Analysis
Moderna Slashes R&D Budget, Stock Plummets Amid Profitability Concerns
Moderna announced plans to slash its R&D budget by $1.1 billion by 2027.
Market Analysis
Big Pharma Stocks: Who’s Leading the Race and Who’s Slipping?
Merck's wider drug moat and acquisition spree makes it a safer bet but VKTX can be the next LLY.
Market Analysis
Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain
Eli Lilly's weight loss drug tirzepatide has received approval from Chinese regulators, intensifying competition with Novo Nordisk.
Market Analysis
Wall Street Weighs in as Pfizer Targets $100 Billion Weight Loss Market
Pfizer announced plans to advance a once-daily version of its weight loss pill, danuglipron, following encouraging early-stage trial results.
Best Stocks
LLY vs NVO: Which One is Likely to Become a $1T Company First
Tackling growing waistlines is expected to yield much shareholder value.